On August 2, 2018, the Board of Directors of Avinger, Inc. decided to combine the positions of Lead Independent Director and chairman of the Board and, following review by the company's compensation consultant, increase the compensation for the chairman of the Board to $25,000. As a result of this action, James G. Cullen will no longer hold the position of Lead Independent Director. Mr. Cullen will continue to hold the following positions with the company- chairman of the Board, member of the audit committee, member of the compensation committee and chairman of the nominating and corporate governance committee.
Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. It has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).
AVINGER, INC. 
